NICE to take longer on kidney anticancers
This article was originally published in Scrip
The UK's National Institute for health and Clinical Excellencehas extended until January its assessment of four kidney cancer drugs, none of which was deemed cost-effective in a draft appraisal issued in August (Scrip Online, August 8th, 2008).
You may also be interested in...
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.